Welcome to our dedicated page for Atossa Therapeutics SEC filings (Ticker: ATOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial timelines, secondary offerings, and evolving patent claims make Atossa Therapeutics filings anything but straightforward. Each 8-K can reveal a pivotal breast-cancer study update or a new equity raise that shifts dilution math overnight. Skimming hundreds of pages to locate these nuggets is a real hurdle for biotech investors.
Stock Titan removes that friction. Our AI reads every incoming document on EDGAR, then delivers plain-English highlights that show exactly where R&D spend changed, which trial cohort advanced, and how many shares management just registered. Whether you need an Atossa Therapeutics quarterly earnings report 10-Q filing breakdown or Atossa Therapeutics 8-K material events explained, the platform serves it in minutes, not hours.
Here’s what you can explore today:
- Real-time alerts for Atossa Therapeutics Form 4 insider transactions real-time—know when executives buy or sell.
- Concise AI notes that make an Atossa Therapeutics annual report 10-K simplified enough to read over coffee.
- Line-by-line Atossa Therapeutics earnings report filing analysis for quick trend checks.
- Instant answers to “Atossa Therapeutics proxy statement executive compensation” or other board-level queries.
From “Atossa Therapeutics insider trading Form 4 transactions” to “understanding Atossa Therapeutics SEC documents with AI,” every disclosure is summarized, searchable, and actionable. Stop digging through PDFs; let our expert system surface the capital raises, patent wins, and trial results that move the stock.
The Vanguard Group filed Amendment No. 2 to Schedule 13G for Daily Journal Corp. (DJCO). As of the event date 06/30/2025, Vanguard reports beneficial ownership of 100,243 DJCO common shares, equal to 7.27 % of the outstanding class.
Voting power is minimal: 0 shares sole and 1,373 shares shared. Dispositive power is larger, with 97,833 shares sole and 2,410 shares shared. Vanguard files under Rule 13d-1(b) in its capacity as an investment adviser ("IA"), indicating the position is held in the ordinary course of business without the intent to influence control. The certification is signed by Ashley Grim, Head of Global Fund Administration, on 07/29/2025.
The amendment confirms Vanguard remains a >5 % passive institutional holder, providing updated ownership details but no indication of strategic changes or control ambitions.
FAQ
What is the current stock price of Atossa Therapeutics (ATOS)?
What is the market cap of Atossa Therapeutics (ATOS)?
What is the primary focus of Atossa Therapeutics Inc?
What is (Z)-endoxifen and why is it significant?
How does Atossa differentiate its drug delivery approach?
What stage is Atossa Therapeutics currently in?
How does the company strengthen its market position?
What are the core components of Atossa’s business model?
Who are the primary beneficiaries of Atossa’s therapies?
How does Atossa’s approach contribute to the field of oncology?
